Clinical trials: TACE
Hepatectomy, Hepatocellular Carcinoma
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and its efficacy is limited. More active treatments were performed in patients with advanced HCC in China, which include radical hepatectomy…
- Conditions
- Hepatectomy, Hepatocellular Carcinoma, Sorafenib
- Trial name
- 2011PTAHCC (NCT01409499)
- Testing
- hepatic resection, transcatheter hepatic arterial chemoembolization, sorafenib
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus TACE (Sin-Bev-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced stage hepatocellular carcinoma (HCC).
- Trial name
- NCT05985798
- Testing
- Sin-Bev-TACE, Len-TACE
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC)
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
The goal of this clinical trial is to compare the safety and efficacy of sequential Transarterial Chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) versus Y90-radioembolisation (SIRT), followed by systemic…
- Trial name
- BIIRTH (NCT07293468)
- Testing
- Transarterial chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), SIRT Yttrium-90
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- Tuen Mun Hospital
Unresectable Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
This is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapies (LRTs), including…
- Trial name
- ISMIO001 (NCT07204327)
- Testing
- Atezo+Bev plus Locoregional Therapy
- Where
- China
- Volunteers
- 1,136 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma
The objective of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma as first line therapy.
- Trial name
- NCT04297280
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.
- Trial name
- NCT04954781
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Liver Cancer
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524316
- Testing
- doxorubicin hydrochloride, sunitinib malate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Purpose: The purpose of this study is to determine the feasibility and safety of using small beads (70-150 micron in place of 100-300 micron) to deliver chemotherapy into the liver to treat patients with liver lesions from…
- Trial name
- NCT02015754
- Testing
- DEBIRI, LC Bead M1, TACE
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yale University
Carcinoma, Hepatocellular
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
REPLACE is a phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of regorafenib and pembrolizumab (Rego-Pembro) versus transarterial chemoembolization (TACE) or transarterial radioembolization…
- Trial name
- REPLACE (NCT04777851)
- Testing
- Regorafenib in combination with pembrolizumab, Loco-regional therapy
- Where
- 26 sites in United States, Belgium and 11 more
- Volunteers
- 45 people
- Sponsor
- Translational Research in Oncology
Liver Cancer
Radiofrequency-assisted Liver Resection in Intractable Liver Cancer
In this retrospective study, the investigators assessed the application of radiofrequency-assisted liver resection in intractable liver cancer resection, and plan to analysis the different factors.
- Trial name
- NCT04413526
- Testing
- radiofrequency, TACE, TACE+radiofrequency
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Hepatocellular Carcinoma
Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker…
- Trial name
- NCT04459468
- Testing
- Lipiodol
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
The purpose of this study is to evaluate overall survival in patients diagnosed with hepatocellular cancer (HCC) treated with HepaSphere/QuadraSphere Microspheres loaded with chemotherapeutic agent doxorubicin compared to…
- Trial name
- HiQuality (NCT01387932)
- Testing
- HepaSphere/QuadraSphere Microspheres, PVA, lipiodol, doxorubicin
- Where
- 23 sites in United States, Belgium and 3 more
- Volunteers
- 235 people
- Sponsor
- Merit Medical Systems, Inc.
Hepatocellular Carcinoma
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
This study aimed to evaluate the efficacy and the safety of the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab Injection in combination with transarterial chemoembolization with drug-eluting beads(TACE-DEB) in patients…
- Trial name
- NCT04174781
- Testing
- Sintilimab, DEB-TACE
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Zhejiang University
HCC
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen
- Trial name
- CHANCE023 (NCT06024252)
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Zhongda Hospital
Hepatocarcinoma
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after…
- Trial name
- NCT06900478
- Testing
- Icariin Soft Capsules+TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hua Li
Unresectable Hepatocellular Carcinoma
A Clinical Study of Precision TACE (P-TACE) With Surefire
The purpose of this research study is to learn about 2 types of FDA-approved catheters used in angiographic (X-ray of blood vessels, with radiopaque substance) procedures like DEB-TACE treatment.
- Trial name
- NCT03345225
- Testing
- SureFire Infusion System, Standard Endhole Microcatheter
- Where
- United States
- Sponsor
- University of Miami
Liver Cancer
Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Trial name
- NCT00293397
- Testing
- Drug-eluting beads loaded with doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5 Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery or local ablative therapy.
- Trial name
- NCT01869088
- Testing
- Recombinant Human Adenovirus Type 5 Injection, Transartery Chemoembolization
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization)
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment…
- Conditions
- HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT
- Trial name
- NCT07351669
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Zhongda Hospital
HCC, Hepatocellular Carcinoma
LifePearl-Doxo Pharmacokinetic (PK) Study
The primary purpose of the study is to evaluate the pharmacokinetic profile, safety, and efficacy of LifePearl™ microspheres loaded with Doxorubicin in the treatment of unresectable HCC.
- Trial name
- NCT02548780
- Testing
- Chemoembolization, Pharmacokinetics
- Where
- 3 sites in Greece, Spain and 1 more
- Volunteers
- 15 people
- Sponsor
- Terumo Europe N.V.